Education
About Us
Working with TipRanks
Follow Us
Immunotech Biopharm Ltd (HK:6978)
:6978
RESEARCH TOOLSreports
Total Valuation
Immunotech Biopharm Ltd has a market cap or net worth of HK$2.04B. The enterprise value is HK$1.93B.
Market CapHK$2.04B
Enterprise ValueHK$1.93B
Share Statistics
Immunotech Biopharm Ltd has 514,584,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding514,584,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Immunotech Biopharm Ltd’s return on equity (ROE) is 14.06 and return on invested capital (ROIC) is -123.86%.
Return on Equity (ROE)14.06
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-123.86%
Return on Capital Employed (ROCE)-1.49
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count154
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio-139.96
Price to Fair Value-83.60
Price to FCF-18.77K
Price to Operating Cash Flow-23.40K
PEG Ratio-298.68
Income Statement
In the last 12 months, Immunotech Biopharm Ltd had revenue of 0.00 and earned -186.91M in profits. Earnings per share was -0.36.
Revenue0.00
Gross Profit0.00
Operating Income-198.78M
Pretax Income-186.42M
Net Income-186.91M
EBITDA-148.68M
Earnings Per Share (EPS)-0.36
Cash Flow
In the last 12 months, operating cash flow was -79.52K and capital expenditures -19.65K, giving a free cash flow of -99.17K billion.
Operating Cash Flow-79.52K
Free Cash Flow-99.17K
Free Cash Flow per Share>-0.01
Dividends & Yields
Immunotech Biopharm Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.21
52-Week Price Change25.00%
50-Day Moving Average3.29
200-Day Moving Average3.00
Relative Strength Index (RSI)71.02
Average Volume (3m)542.70K
Important Dates
Immunotech Biopharm Ltd upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Immunotech Biopharm Ltd as a current ratio of 0.20, with Debt / Equity ratio of -875.92%
Current Ratio0.20
Quick Ratio0.19
Debt to Market Cap0.00
Net Debt to EBITDA-0.47
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immunotech Biopharm Ltd has paid 926.00K in taxes.
Income Tax926.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Immunotech Biopharm Ltd EV to EBITDA ratio is -7.94, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA-7.94
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
Immunotech Biopharm Ltd has HK$57.49M in cash and marketable securities with ¥116.46M in debt, giving a net cash position of HK$58.97M billion.
Cash & Marketable SecuritiesHK$57.49M
Total Debt¥116.46M
Net CashHK$58.97M
Net Cash Per ShareHK$0.11
Tangible Book Value Per Share-HK$0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immunotech Biopharm Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast44.88%